Loading...

I Henderson, MD

Address3333 California Street
San Francisco CA 94118
Phone415-353-7070
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Henderson I. With Decades of Perspective, Craig Henderson Observes That Treatment of Breast Cancer Has Come a Long Way. Oncology (Williston Park). 2017 05 15; 31(5):346-8. PMID: 28516433.
      View in: PubMed
    2. Henderson I. Targeted therapy: a sea change in the treatment of cancer. Oncology (Williston Park). 2012 Nov; 26(11):1035, 1039. PMID: 23330342.
      View in: PubMed
    3. Lara JF, Thor AD, Dressler LG, Broadwater G, Bleiweiss IJ, Edgerton S, Cowan D, Goldstein LJ, Martino S, Ingle JN, Henderson I, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, Hayes DF. p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Clin Cancer Res. 2011 Aug 01; 17(15):5170-8. PMID: 21693655; PMCID: PMC3149770.
    4. Henderson I. Can we abandon anthracyclines for early breast cancer patients? Oncology (Williston Park). 2011 Feb; 25(2):115-24, 127. PMID: 21456382.
      View in: PubMed
    5. Henderson I. Adjuvant chemotherapy is not for everyone. Breast Cancer Res Treat. 2010 Aug; 123(1):159-62. PMID: 20549338.
      View in: PubMed
    6. Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Lichter AS, Schneider DJ, Abeloff MD, Henderson I, Muss HB, Green SJ, Lew D, Livingston RB, Martino S, Osborne CK. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009 Dec 19; 374(9707):2055-63. PMID: 20004966; PMCID: PMC3140679.
    7. Marks LB, Cirrincione C, Fitzgerald TJ, Laurie F, Glicksman AS, Vredenburgh J, Prosnitz LR, Shpall EJ, Crump M, Richardson PG, Schuster MW, Ma J, Peterson BL, Norton L, Seagren S, Henderson I, Hurd DD, Peters WP. Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082. Int J Radiat Oncol Biol Phys. 2010 Apr; 76(5):1305-13. PMID: 19747781; PMCID: PMC3670136.
    8. DiGiovanna MP, Stern DF, Edgerton S, Broadwater G, Dressler LG, Budman DR, Henderson I, Norton L, Liu ET, Muss HB, Berry DA, Hayes DF, Thor AD. Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. J Clin Oncol. 2008 May 10; 26(14):2364-72. PMID: 18390970.
      View in: PubMed
    9. Lamont EB, Herndon JE, Weeks JC, Henderson I, Lilenbaum R, Schilsky RL, Christakis NA. Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants. Med Care. 2008 Mar; 46(3):303-8. PMID: 18388845; PMCID: PMC4158032.
    10. Liu MC, Demetri GD, Berry DA, Norton L, Broadwater G, Robert NJ, Duggan D, Hayes DF, Henderson I, Lyss A, Hopkins J, Kaufman PA, Marcom PK, Younger J, Lin N, Tkaczuk K, Winer EP, Hudis CA. Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. Cancer Treat Rev. 2008 May; 34(3):223-30. PMID: 18234424; PMCID: PMC2651678.
    11. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson I, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007 Oct 11; 357(15):1496-506. PMID: 17928597.
      View in: PubMed
    12. Muss HB, Berry DA, Cirrincione C, Budman DR, Henderson I, Citron ML, Norton L, Winer EP, Hudis CA. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol. 2007 Aug 20; 25(24):3699-704. PMID: 17704418.
      View in: PubMed
    13. Henderson I, Bhatia V. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert Rev Anticancer Ther. 2007 Jul; 7(7):919-43. PMID: 17627452.
      View in: PubMed
    14. Lamont EB, Herndon JE, Weeks JC, Henderson I, Earle CC, Schilsky RL, Christakis NA. Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst. 2006 Sep 20; 98(18):1335-8. PMID: 16985253; PMCID: PMC4158031.
    15. Berry DA, Cirrincione C, Henderson I, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006 Apr 12; 295(14):1658-67. PMID: 16609087; PMCID: PMC1459540.
    16. Henderson I. Axillary surgery: clinical judgment required. J Clin Oncol. 2006 Jan 20; 24(3):325-6. PMID: 16344313.
      View in: PubMed
    17. Kumar AS, Bhatia V, Henderson I. Overdiagnosis and overtreatment of breast cancer: rates of ductal carcinoma in situ: a US perspective. Breast Cancer Res. 2005; 7(6):271-5. PMID: 16457703; PMCID: PMC1410763.
    18. Henderson I, Piccart-Gebhart MJ. The evolving role of aromatase inhibitors in adjuvant breast cancer therapy. Clin Breast Cancer. 2005 Aug; 6(3):206-15. PMID: 16137430.
      View in: PubMed
    19. Lamont EB, Herndon JE, Weeks JC, Henderson I, Lilenbaum R, Schilsky RL, Christakis NA. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst. 2005 Jul 20; 97(14):1080-3. PMID: 16030306.
      View in: PubMed
    20. Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, Griffin S, Miller A, Tse J, Novotny D, Persons DL, Barcos M, Henderson I, Liu ET, Thor A, Budman D, Muss H, Norton L, Hayes DF. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol. 2005 Jul 01; 23(19):4287-97. PMID: 15994142.
      View in: PubMed
    21. Overmoyer B, Silverman P, Holder LW, Tripathy D, Henderson I. Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer. Clin Breast Cancer. 2005 Jun; 6(2):150-7. PMID: 16001993.
      View in: PubMed
    22. Bellon JR, Come SE, Gelman RS, Henderson I, Shulman LN, Silver BJ, Harris JR, Recht A. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol. 2005 Mar 20; 23(9):1934-40. PMID: 15774786.
      View in: PubMed
    23. Muss HB, Woolf S, Berry D, Cirrincione C, Weiss RB, Budman D, Wood WC, Henderson I, Hudis C, Winer E, Cohen H, Wheeler J, Norton L. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005 Mar 02; 293(9):1073-81. PMID: 15741529.
      View in: PubMed
    24. Henderson I. Aromatase inhibitors in the management of early breast cancer: optimizing the clinical benefit. Semin Oncol. 2004 Dec; 31(6 Suppl 12):31-4. PMID: 15719599.
      View in: PubMed
    25. Robert NJ, Vogel CL, Henderson I, Sparano JA, Moore MR, Silverman P, Overmoyer BA, Shapiro CL, Park JW, Colbern GT, Winer EP, Gabizon AA. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Semin Oncol. 2004 Dec; 31(6 Suppl 13):106-46. PMID: 15717740.
      View in: PubMed
    26. Sartor CI, Peterson BL, Woolf S, Fitzgerald TJ, Laurie F, Turrisi AJ, Bogart J, Henderson I, Norton L. Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344. J Clin Oncol. 2005 Jan 01; 23(1):30-40. PMID: 15545661.
      View in: PubMed
    27. Keller AM, Mennel RG, Georgoulias VA, Nabholtz JM, Erazo A, Lluch A, Vogel CL, Kaufmann M, von Minckwitz G, Henderson I, Mellars L, Alland L, Tendler C. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol. 2004 Oct 01; 22(19):3893-901. PMID: 15459210.
      View in: PubMed
    28. Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, Wheeler J, Champion LA, Smith TJ, Smith BL, Shapiro C, Muss HB, Winer E, Hudis C, Wood W, Sugarbaker D, Henderson I, Norton L. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004 Sep 02; 351(10):971-7. PMID: 15342805.
      View in: PubMed
    29. Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, Michaelson RA, Kirshner JA, Fleming GF, Perry MC, Graham ML, Sharp SA, Keresztes R, Henderson I, Hudis C, Muss H, Norton L. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol. 2004 Jun 01; 22(11):2061-8. PMID: 15169793.
      View in: PubMed
    30. Weiss RB, Woolf SH, Demakos E, Holland JF, Berry DA, Falkson G, Cirrincione CT, Robbins A, Bothun S, Henderson I, Norton L. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. J Clin Oncol. 2003 May 01; 21(9):1825-35. PMID: 12721260.
      View in: PubMed
    31. Henderson I, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E, Schilsky RL, Wood WC, Muss HB, Norton L. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):976-83. PMID: 12637460.
      View in: PubMed
    32. Carlson RW, Henderson I. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. Breast Cancer Res Treat. 2003; 80 Suppl 1:S19-26; discussion S27-8. PMID: 14535531.
      View in: PubMed
    33. Henderson I. A rose is no longer a rose. J Clin Oncol. 2002 Aug 15; 20(16):3365-8. PMID: 12177095.
      View in: PubMed
    34. Guidi AJ, Berry DA, Broadwater G, Helmchen B, Bleiweiss IJ, Budman DR, Henderson I, Norton L, Hayes DF. Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869. J Clin Oncol. 2002 Feb 01; 20(3):732-42. PMID: 11821455.
      View in: PubMed
    35. Berry DA, Broadwater G, Klein JP, Antman K, Aisner J, Bitran J, Costanza M, Freytes CO, Stadtmauer E, Gale RP, Henderson I, Lazarus HM, McCarthy PL, Norton L, Parnes H, Pecora A, Perry MC, Rowlings P, Spitzer G, Horowitz MM. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 2002 Feb 01; 20(3):743-50. PMID: 11821456.
      View in: PubMed
    36. Henderson I, Patek AJ. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat. 1998; 52(1-3):261-88. PMID: 10066087.
      View in: PubMed
    37. Roach M, Cirrincione C, Budman D, Hayes D, Berry D, Younger J, Hart R, Henderson I. Race and survival from breast cancer: based on Cancer and Leukemia Group B trial 8541. Cancer J Sci Am. 1997 Mar-Apr; 3(2):107-12. PMID: 9099461.
      View in: PubMed
    38. Smith G, Henderson I. New treatments for breast cancer. Semin Oncol. 1996 Aug; 23(4):506-28. PMID: 8757276.
      View in: PubMed
    39. Henderson I. Using clinical trial information in the practice of medicine. Cancer J Sci Am. 1995 Jul-Aug; 1(2):101-3. PMID: 9166459.
      View in: PubMed
    40. Smith GA, Henderson I. High-dose chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) for the treatment of breast cancer: the jury is still out. Important Adv Oncol. 1995; 201-14. PMID: 7672807.
      View in: PubMed
    41. Henderson I. Adjuvant systemic therapy for early breast cancer. Cancer. 1994 Jul 01; 74(1 Suppl):401-9. PMID: 8004613.
      View in: PubMed
    42. Gray JW, Collins C, Henderson I, Isola J, Kallioniemi A, Kallioniemi OP, Nakamura H, Pinkel D, Stokke T, Tanner M. Molecular cytogenetics of human breast cancer. Cold Spring Harb Symp Quant Biol. 1994; 59:645-52. PMID: 7587125.
      View in: PubMed
    43. Wong K, Henderson I. Management of metastatic breast cancer. World J Surg. 1994 Jan-Feb; 18(1):98-111. PMID: 7910993.
      View in: PubMed
    44. Henderson I. Risk factors for breast cancer development. Cancer. 1993 Mar 15; 71(6 Suppl):2127-40. PMID: 8443762.
      View in: PubMed
    45. Henderson I. Adjuvant systemic therapy: overview. Recent Results Cancer Res. 1993; 127:197-200. PMID: 8502816.
      View in: PubMed
    46. Tripathy D, Henderson I. Systemic adjuvant therapy for breast cancer. Curr Opin Oncol. 1992 Dec; 4(6):1041-9. PMID: 1457518.
      View in: PubMed
    47. Henderson I. Biologic variations of tumors. Cancer. 1992 Apr 01; 69(7 Suppl):1888-95. PMID: 1544087.
      View in: PubMed
    I's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP